Antitumor agents 220. Antitumor-promoting effects of cimigenol and related compounds on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis

Bioorg Med Chem. 2003 Mar 20;11(6):1137-40. doi: 10.1016/s0968-0896(02)00432-7.

Abstract

Cimigenol (1) and 39 related compounds were screened as potential antitumor promoters by examining the ability of the compounds to inhibit Epstein-Barr virus early antigen (EBV-EA) activation (induced by 12-O-tetradecanoylphorbol-13-acetate) in Raji cells. Structure-activity relationship analysis indicated that compound 1 showed the highest activity and also exhibited significant inhibitory effects on mouse skin tumor promotion in an in vivo two-stage carcinogenesis test. These data suggest that 1 and the related compounds might be valuable anti-tumor promoters.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 9,10-Dimethyl-1,2-benzanthracene / antagonists & inhibitors
  • Animals
  • Anticarcinogenic Agents / pharmacology*
  • Carcinogens
  • Cell Survival / drug effects
  • Cimicifuga / chemistry
  • Female
  • Herpesvirus 4, Human / drug effects*
  • Lanosterol / analogs & derivatives
  • Lanosterol / chemical synthesis*
  • Lanosterol / pharmacology*
  • Mice
  • Mice, Inbred ICR
  • Papilloma / chemically induced
  • Papilloma / prevention & control*
  • Skin Neoplasms / chemically induced
  • Skin Neoplasms / prevention & control*

Substances

  • (23R,24S)-16,23-16,24-diepoxy-9,19-cyclolanostan-3beta,15alpha,25-triol
  • Anticarcinogenic Agents
  • Carcinogens
  • Lanosterol
  • 9,10-Dimethyl-1,2-benzanthracene